Alaproclate

Alaproclate
Clinical data
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: uncontrolled
Identifiers
IUPAC name
  • 1-(4-Chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18ClNO2
Molar mass255.74 g·mol−1
3D model (JSmol)
SMILES
  • Clc1ccc(cc1)CC(OC(=O)C(N)C)(C)C
InChI
  • InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3 checkY
  • Key:FZSPJBYOKQPKCD-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Alaproclate (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.[1][2]

See also

References

  1. ↑ Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE (December 1994). "Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow". The Journal of Pharmacology and Experimental Therapeutics. 271 (3): 1314–9. PMID 7996440.
  2. ↑ Nicholson KL, Balster RL (November 2003). "Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats". Psychopharmacology. 170 (2): 215–24. doi:10.1007/s00213-003-1527-6. PMID 12851738. S2CID 30803162.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.